1. World Health Organization. WHO Technical Report Series, No.961, 2011. Annex 9 Model guidance for the storage and transport of time- and temperature-sensitive pharmaceutical products (2011). https://www.who.int/medicines/areas/quality_safety/quality_assurance/ModelGuidanceForStorageTransportTRS961Annex9.pdf?ua=1. Accessed 22 Jan 2021.
2. European Commission. Guidelines of 5 November 2013 on Good Distribution Practice of medicinal products for human use. Official Journal of the European Union (2013). https://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:C:2013:343:0001:0014:EN:PDF. Accessed 2 Mar 2021.
3. Marco Garbayo, J. L., Cuellar Monreal, M. J., Perez Castello, I., Castello Escriva, I. & Muelas Tirado, J. Pelegri Sebastia. J. Pharmaceut. Care Esp. 10, 40–43 (2008).
4. Cuéllar, M. J., Marco, J. L., Pérez-Castelló, I. & Castelló Escrivá, A. Calidad en la conservación de los medicamentos termolábiles en el ámbito domiciliario (Quality of storage of thermolabile drugs in patients’ homes). Rev. Calid Asist. 25, 64–69. https://doi.org/10.1016/j.cali.2009.09.001 (2010).
5. Vlieland, N. D., Gardarsdottir, H., Bouvy, M. L., Egberts, T. C. & van den Bemt, B. J. The majority of patients do not store their biologic disease-modifying antirheumatic drugs within the recommended temperature range. Rheumatology (Oxford) 55, 704–709. https://doi.org/10.1093/rheumatology/kev394 (2016).